Effect of Atorvastatin Monotherapy and Low-Dose Atorvastatin/Ezetimibe Combination on Fasting and Postprandial Triglycerides in Combined Hyperlipedemia
Effect of Atorvastatin Monotherapy and Low-Dose Atorvastatin/Ezetimibe Combination on Fasting and Postprandial Triglycerides in Combined Hyperlipedemia
复制标题
DOI：
10.1177/1074248411399762
复制
发表时间：
2012-03-01
影响因子：
2.6
通讯作者：
Choi, Donghoon
中科院分区：
文献类型：
--
作者：
Lee, Sang-Hak;Park, Sungha;Choi, Donghoon
餐后甘油三酯（TG）水平很容易测量，并且与未来的心血管风险相关。本研究的目的是比较他汀类药物单药治疗和低剂量他汀类药物/依折麦布对血脂参数（包括空腹和餐后TG）的影响。经过4周的饮食导入期后，78名混合性高脂血症患者被随机分配到2个治疗组中的1个，持续8周：阿托伐他汀20 mg或阿托伐他汀/依折麦布5 mg/5 mg。在药物治疗期前后进行口服脂肪负荷试验。与阿托伐他汀单药治疗相比，低剂量联合治疗有降低空腹TG的趋势。联合治疗方案显示，阿托伐他汀组和联合治疗组餐后TG（分别为13%+/-42%和34%+/-30%，P = 0.03）和总胆固醇（TC; P = 0.03）降低幅度更大。低密度脂蛋白胆固醇（LDL-C）和高密度脂蛋白胆固醇（HDL-C）的变化在两组之间没有差异。联合用药组的apo B/A1降低幅度更大（阿托伐他汀组和联合用药组分别为-32%+/-19%和-42%+/-13%，P = 0.02）。总之，这些结果证明了低剂量阿托伐他汀/依折麦布联合治疗在混合型高脂血症患者中降低LDL-C后对餐后TG控制的潜在有益作用。
Postprandial triglyceride (TG) levels are easy to measure and are associated with future cardiovascular risk. The aim of this study was to compare the effects of statin monotherapy and low-dose statin/ezetimibe on lipid parameters including fasting and postprandial TG. After a 4-week dietary run-in period, 78 patients with combined hyperlipidemia were randomized into 1 of 2 treatment groups for 8 weeks: atorvastatin 20 mg or atorvastatin/ezetimibe 5 mg/5 mg. An oral fat load test was performed before and after the drug-treatment period. The low-dose combination had a tendency to decrease fasting TG more than atorvastatin monotherapy. The combination regimen showed a greater reduction in postprandial TG (13% +/- 42% and 34% +/- 30%, in the atorvastatin and combination groups, respectively, P = .03) and total cholesterol (TC; P = .03). The changes in low-density lipoprotein-cholesterol (LDL-C) and high-density lipoprotein-cholesterol (HDL-C) were not different between the 2 groups. The reduction in apo B/A1 was greater in the combination group (-32% +/- 19% and -42% +/- 13%, in the atorvastatin and combination groups, respectively, P = .02). In conclusion, these results demonstrated a potential beneficial effect of low-dose atorvastatin/ezetimibe combination treatment on postprandial TG control after comparable LDL-C lowering in patients with combined hyperlipidemia.